We currently have a study in Canada for patients with Relapsing-Remitting Multiple Sclerosis (RRMS). We want to learn about the gastrointestinal side effects of oral disease-modifying treatments (DMTs) such as Aubagio. We are looking for patients who have been diagnosed with RRMS and have experienced gastrointestinal related symptoms while taking one of those medications, either currently or within the last 12 weeks. You may be currently taking one of these medications or might have discontinued taking the medication – we are interested in both sides.
If you qualify for this study, you will be asked to participate in a telephone interview lasting around 60-90 minutes. Eligible participants who participate in the interview will receive $275 CAD ($200 CAD for participation and $75 CAD for providing confirmation of diagnosis) If you or someone you know has a diagnosis of relapsing-remitting multiple sclerosis and have experienced gastrointestinal adverse events from treatment and are interested in participating or would like more information about the study, please contact me at [email protected]
Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.